Ann: IHL-42X patent update & open label extension study approval, page-184

Another key insight to take away from this extension study is why would the lowest dose have been recommended as a starting point, one could conclude that this level has shown enough of a reduction to warrant further research, which also bodes well for less side effects for long term use.

The dosing will commence with the lowest dose, as defined in IHLOSAPOC1, low (2.5 mg dronabinol 125 mg acetazolamide). If the drug combination is not effective at reducing the sleep apnoea symptoms in a participant, as determined by the patient reported outcomes and AHI measured at each PSG, the dose may be increased to the medium dose, medium (5 mg dronabinol 250 mg acetazolamide) at the discretion of the investigator.